Riluzole

Riluzole may protect motor nerves from further deterioration by reducing glutamate levels in the brain and spinal cord by blocking its release from nerve terminals.

Status

Type: Small Molecule
Stage: FDA-Approved
Status: FDA-Approved

TDI Says:

Although it only has modest effects on disease progression, riluzole is the only FDA-approved drug for ALS.

Learn More

  • Postcard from Australia

    Neuroscience Research Australia’s Steve Vucic PhD discusses emerging combination treatment strategies including riluzole that may reduce hyperexcitability, a potential early step in the disease.

Published Results

Comment on this Topic

(All comments are moderated before they appear here.)
×
End of Year Appeal 2019 End of Year Appeal 2019
Join the race to End ALS
Support the advancement of promising treatments to help David and others with ALS.
Support the advancement of promising treatments
to help David and others with ALS.